{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:01:03Z","timestamp":1784764863624,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100016304","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016304","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvascsurg.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Vascular Surgery"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jvs.2026.03.629","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T09:01:22Z","timestamp":1775898082000},"page":"448-458.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of antithrombotic therapies for peripheral arterial disease"],"prefix":"10.1016","volume":"84","author":[{"given":"Uday","family":"Dhanda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3160-9938","authenticated-orcid":false,"given":"Dana","family":"Alameddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3548-3420","authenticated-orcid":false,"given":"Kurt S.","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6315-5435","authenticated-orcid":false,"given":"Lydia","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin D.","family":"Slade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loay","family":"Kabbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul J.","family":"Guzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6572-8658","authenticated-orcid":false,"given":"Ira L.","family":"Leeds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0046-752X","authenticated-orcid":false,"given":"Cassius Iyad","family":"Ochoa Chaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvs.2026.03.629_bib1","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1161\/ATVBAHA.120.314595","article-title":"Epidemiology and risk of amputation in patients with diabetes mellitus and peripheral artery disease","volume":"40","author":"Barnes","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jvs.2026.03.629_bib2","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s40265-022-01756-6","article-title":"Antithrombotic therapy for symptomatic peripheral arterial disease: a systematic review and network meta-analysis","volume":"82","author":"Willems","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.jvs.2026.03.629_bib3","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jvs.2010.04.027","article-title":"Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial","volume":"52","author":"Belch","year":"2010","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jvs.2026.03.629_bib4","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.120.009584","article-title":"Contemporary review of antithrombotic therapy in peripheral artery disease","volume":"13","author":"Hess","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jvs.2026.03.629_bib5","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1007\/s11239-021-02417-3","article-title":"The efficacy and safety of direct oral anticoagulants plus aspirin in symptomatic lower extremity peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials","volume":"52","author":"Costa","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jvs.2026.03.629_bib6","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvs.2026.03.629_bib7","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.jvs.2016.05.098","article-title":"Dual antiplatelet therapy is associated with prolonged survival after lower extremity revascularization","volume":"64","author":"Soden","year":"2016","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jvs.2026.03.629_bib8","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvs.2026.03.629_bib9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40256-023-00620-6","article-title":"The cost-effectiveness of rivaroxaban plus aspirin compared with aspirin alone in the COMPASS trial: a US perspective","volume":"24","author":"Lamy","year":"2024","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jvs.2026.03.629_bib10","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.amepre.2017.11.013","article-title":"Recommendations of the second panel on cost effectiveness in health and medicine: a reference, not a rule book","volume":"54","author":"Carias","year":"2018","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.jvs.2026.03.629_bib11","series-title":"Cost-Effectiveness in Health and Medicine","author":"Neumann","year":"2017"},{"key":"10.1016\/j.jvs.2026.03.629_bib12","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1345\/aph.1E367","article-title":"Cost-effectiveness of fluvastatin following successful first percutaneous coronary intervention","volume":"39","author":"Delea","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jvs.2026.03.629_bib13","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.atherosclerosis.2014.06.027","article-title":"Clinical- and cost-effectiveness of LDL particle-guided statin therapy: a simulation study","volume":"236","author":"Folse","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jvs.2026.03.629_bib14","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.2016.11004","article-title":"Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease","volume":"316","author":"Kazi","year":"2016","journal-title":"Jama"},{"key":"10.1016\/j.jvs.2026.03.629_bib15","doi-asserted-by":"crossref","first-page":"252","DOI":"10.4070\/kcj.2018.0220","article-title":"Cost-Effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation","volume":"49","author":"Kim","year":"2019","journal-title":"Korean Circ J"},{"key":"10.1016\/j.jvs.2026.03.629_bib16","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/13696998.2020.1724119","article-title":"Cost-effective analysis of clopidogrel versus aspirin for high risk patients with established peripheral arterial disease in China","volume":"23","author":"Lin","year":"2020","journal-title":"J Med Econ"},{"key":"10.1016\/j.jvs.2026.03.629_bib17","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.jvs.2020.08.129","article-title":"The cost-effectiveness of intensive low-density lipoprotein cholesterol lowering in people with peripheral artery disease","volume":"73","author":"Nastasi","year":"2021","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jvs.2026.03.629_bib18","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/clc.22756","article-title":"Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome","volume":"40","author":"Jiang","year":"2017","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jvs.2026.03.629_bib19","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1067\/mva.2001.115961","article-title":"Cost-effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery","volume":"34","author":"Oostenbrink","year":"2001","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jvs.2026.03.629_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213499","article-title":"Cost-effectiveness of increased influenza vaccination uptake against readmissions of major adverse cardiac events in the US","volume":"14","author":"Peasah","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jvs.2026.03.629_bib21","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ahj.2009.02.017","article-title":"Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes","volume":"157","author":"Sculpher","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.jvs.2026.03.629_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003883","article-title":"Cost-effectiveness of new cardiac and vascular rehabilitation strategies for patients with coronary artery disease","volume":"3","author":"Spronk","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.jvs.2026.03.629_bib23","doi-asserted-by":"crossref","first-page":"E706","DOI":"10.9778\/cmajo.20200107","article-title":"Cost-effectiveness of antithrombotic agents for atrial fibrillation in older adults at risk for falls: a mathematical modelling study","volume":"8","author":"Wong","year":"2020","journal-title":"CMAJ Open"},{"key":"10.1016\/j.jvs.2026.03.629_bib24","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvs.2026.03.629_bib25","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.amjmed.2004.01.014","article-title":"Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis","volume":"116","author":"Schleinitz","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.jvs.2026.03.629_bib26","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1074248418784940","article-title":"Sodium nitrite-mediated cardioprotection in primary percutaneous coronary intervention for ST-Segment elevation myocardial infarction: a cost-effectiveness analysis","volume":"24","author":"Jones","year":"2019","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.jvs.2026.03.629_bib27","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.ejvs.2021.02.039","article-title":"Clinical benefit, harm, and cost effectiveness of screening men for peripheral artery disease: a markov model based on the VIVA trial","volume":"61","author":"Lindholt","year":"2021","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jvs.2026.03.629_bib28","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00228-024-03794-3","article-title":"Cost-effectiveness of rivaroxaban plus aspirin versus aspirin alone in patients with stable coronary artery disease or peripheral artery disease: a systematic review","volume":"81","author":"Arabloo","year":"2025","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jvs.2026.03.629_bib29","first-page":"1570","article-title":"FDA approves generic form of rivaroxaban for CAD and PAD","volume":"333","author":"Anderer","year":"2025","journal-title":"Jama"},{"key":"10.1016\/j.jvs.2026.03.629_bib30","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jvs.2025.10.101","article-title":"A systematic review and meta-analysis of the impact of clopidogrel responsiveness on ischemic and bleeding complications after noncoronary endovascular procedures","volume":"83","author":"Zhang","year":"2026","journal-title":"J Vasc Surg"}],"container-title":["Journal of Vascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0741521426008621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0741521426008621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:02:35Z","timestamp":1784761355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0741521426008621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0741521426008621"],"URL":"https:\/\/doi.org\/10.1016\/j.jvs.2026.03.629","relation":{},"ISSN":["0741-5214"],"issn-type":[{"value":"0741-5214","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of antithrombotic therapies for peripheral arterial disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Vascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvs.2026.03.629","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Society for Vascular Surgery. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}